Bone morphogenetic protein-SMAD signaling pathway (BMP-SMAD signaling pathway)

The **bone morphogenetic protein-SMAD signaling pathway** is a canonical intracellular signal transduction cascade initiated by members of the bone morphogenetic protein (BMP) family binding to their cell surface receptors. This leads to phosphorylation and activation of receptor-regulated SMAD proteins (R-Smads), which then form complexes with co-mediator Smads. These complexes translocate into the nucleus where they regulate transcriptional programs critical for cellular differentiation, especially in osteoblasts and osteoclasts during bone formation and remodeling. The BMP–SMAD axis is essential not only for skeletal homeostasis but also plays key roles in embryonic patterning, cartilage development, neural specification, adipogenesis, heart formation, and more. Dysregulation can contribute to diseases such as osteoporosis, cancer progression/metastasis involving the skeleton or stroma, congenital malformations affecting bones/cartilage/organism derived from mesoderm/endoderm layers. Drugs like luspatercept act by modulating this pathway for therapeutic benefit in conditions like anemia associated with myelodysplastic syndromes by targeting late-stage erythropoiesis through altered SMAD signaling dynamics. Note: The "bone morphogenetic protein–SMAD signaling pathway" refers to a molecular process/pathway rather than a single molecule/receptor; thus it is not considered a direct therapeutic target itself but rather an ensemble mechanism that includes multiple druggable components such as specific BMP ligands/receptors or individual SMAD proteins.

Other names

BMP/SMAD pathwayBone morphogenetic protein/SMAD signalingBMP-Smad axisTGF-beta/BMP-Smad pathway (when referring to overlap with TGF-beta)

Modulation of SMAD-mediated transcription downstream of BMP receptors, affecting gene expression related to bone formation, erythropoiesis, or other developmental processes.